152 related articles for article (PubMed ID: 20978876)
1. Postremission gemtuzumab ozogamicin for elderly patients with acute myelogenous leukemia with favorable characteristics and comorbid conditions.
Ichikawa M; Hangaishi A; Nannya Y; Kurokawa M
Int J Hematol; 2010 Nov; 92(4):673-4. PubMed ID: 20978876
[No Abstract] [Full Text] [Related]
2. Low dose gemtuzumab ozogamicin for relapsed acute myeloid leukaemia in elderly.
Piccaluga PP; Martinelli G; Rondoni M; Malagola M; Ronconi S; Visani G; Baccarani M
Haematologica; 2003 Dec; 88(12):ECR37. PubMed ID: 14688010
[No Abstract] [Full Text] [Related]
3. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
4. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia.
Stasi R
Expert Opin Biol Ther; 2008 Apr; 8(4):527-40. PubMed ID: 18352855
[TBL] [Abstract][Full Text] [Related]
5. Gemtuzumab ozogamicin: time to resurrect?
Ravandi F; Estey EH; Appelbaum FR; Lo-Coco F; Schiffer CA; Larson RA; Burnett AK; Kantarjian HM
J Clin Oncol; 2012 Nov; 30(32):3921-3. PubMed ID: 22987091
[No Abstract] [Full Text] [Related]
6. Gemtuzumab ozogamicin: is there room for salvage?
Clarke WT; Marks PW
Blood; 2010 Oct; 116(14):2618-9. PubMed ID: 20930085
[No Abstract] [Full Text] [Related]
7. Gemtuzumab Ozogamicin is a promising post-remission therapy for acute myeloid leukemia.
El Kinge AR; Hatoum HA; Mahfouz RA; Otrock ZK; Jabbour E; Kantarjian H; Bazarbachi A
Leuk Res; 2009 Apr; 33(4):565-6. PubMed ID: 18571231
[No Abstract] [Full Text] [Related]
8. Low-dose Gemtuzumab-Ozogamicin as post-consolidation therapy in elderly patients with acute myeloid leukaemia: a pilot study.
Poloni A; Capelli D; Trappolini S; Costantini B; Montanari M; Gini G; Scortechini I; Mancini G; Discepoli G; Leoni P; Olivieri A
Br J Haematol; 2010 Jul; 150(1):119-21. PubMed ID: 20377587
[No Abstract] [Full Text] [Related]
9. What role does gemtuzumab ozogamicin have in the treatment of acute myelogenous leukemia?
Molnár I; Powell BL
Curr Hematol Malig Rep; 2007 May; 2(2):104-10. PubMed ID: 20425358
[TBL] [Abstract][Full Text] [Related]
10. Influence of NPM1 and FLT3-ITD status on outcome in relapsed/refractory AML patients receiving salvage therapy including gemtuzumab ozogamicin.
Chevallier P; Prebet T; Pigneux A; Hunault M; Delaunay J; Perry F; Lode L; Richebourg S; Blanchet O; Vey N; Ifrah N; Milpied N; Blaise D; Harousseau JL; Mohty M
Leukemia; 2010 Feb; 24(2):467-9. PubMed ID: 19847200
[No Abstract] [Full Text] [Related]
11. [Revision of treatment with gemtuzumab ozogamicin using 3 clinical case studies].
Fernández Cañabate E; Longoni Merino M; Estany Raluy C; Pla Poblador R
Farm Hosp; 2008; 32(6):360-2. PubMed ID: 19232223
[No Abstract] [Full Text] [Related]
12. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study.
Löwenberg B; Beck J; Graux C; van Putten W; Schouten HC; Verdonck LF; Ferrant A; Sonneveld P; Jongen-Lavrencic M; von Lilienfeld-Toal M; Biemond BJ; Vellenga E; Breems D; de Muijnck H; Schaafsma R; Verhoef G; Döhner H; Gratwohl A; Pabst T; Ossenkoppele GJ; Maertens J; ; ;
Blood; 2010 Apr; 115(13):2586-91. PubMed ID: 20103782
[TBL] [Abstract][Full Text] [Related]
13. Sensorimotor peripheral neuropathy in an elderly AML patient in complete remission while receiving gemtuzumab ozogamicin as maintenance therapy.
Romani C; Murru R; Adamo F; Di Tucci A; Sabiu D; Casula P; Angelucci E
Ann Hematol; 2006 Jun; 85(6):411-2. PubMed ID: 16538500
[No Abstract] [Full Text] [Related]
14. Trials with gemtuzumab ozogamicin (Mylotarg) combined with chemotherapy regimens in acute myeloid leukemia.
Stadtmauer EA
Clin Lymphoma; 2002 Mar; 2 Suppl 1():S24-8. PubMed ID: 11970767
[TBL] [Abstract][Full Text] [Related]
15. Haematological cancer: Gemtuzumab ozogamicin in acute myeloid leukaemia.
Ravandi F; Kantarjian H
Nat Rev Clin Oncol; 2012 May; 9(6):310-1. PubMed ID: 22547217
[No Abstract] [Full Text] [Related]
16. Successful treatment with gemtuzumab ozogamicin and donor lymphocyte infusion for acute myeloid leukemia relapsing after allogeneic stem cell transplantation.
Tachibana T; Tanaka M; Takasaki H; Numata A; Fujisawa S; Maruta A; Harada H; Mori H; Ishigatsubo Y; Kanamori H
Int J Hematol; 2011 Dec; 94(6):580-2. PubMed ID: 22135078
[No Abstract] [Full Text] [Related]
17. Comparative efficacy and safety of gemtuzumab ozogamicin monotherapy and high-dose cytarabine combination therapy in patients with acute myeloid leukemia in first relapse.
Leopold LH; Berger MS; Cheng SC; Cortes-Franco JE; Giles FJ; Estey EH
Clin Adv Hematol Oncol; 2003 Apr; 1(4):220-5. PubMed ID: 16224410
[TBL] [Abstract][Full Text] [Related]
18. Complete molecular remission in refractory acute myeloid leukemia with MLL/AF9 treated with gemtuzumab ozogamicin.
Asano H; Yamamoto G; Hosoi M; Takahashi T; Hangaishi A; Kurokawa M
Leuk Res; 2010 Jul; 34(7):e152-3. PubMed ID: 20061019
[No Abstract] [Full Text] [Related]
19. Targeting leukemia cells with gemtuzumab ozogamicin.
Treish IM
Cancer Pract; 2000; 8(5):254-7. PubMed ID: 11898239
[No Abstract] [Full Text] [Related]
20. Successful treatment with gemtuzumab ozogamicin monotherapy in a pediatric patient with resistant relapse of acute myeloid leukemia.
Unal S; Cakir M; Kuşkonmaz B; Cetin M; Tuncer AM
Turk J Pediatr; 2009; 51(1):69-71. PubMed ID: 19378895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
